MXPA04003124A - Composicion farmaceutica que comprende un agonista de adenosina a1/a2 y un inhibidor de intercambiadores sodio-hidrogeno. - Google Patents
Composicion farmaceutica que comprende un agonista de adenosina a1/a2 y un inhibidor de intercambiadores sodio-hidrogeno.Info
- Publication number
- MXPA04003124A MXPA04003124A MXPA04003124A MXPA04003124A MXPA04003124A MX PA04003124 A MXPA04003124 A MX PA04003124A MX PA04003124 A MXPA04003124 A MX PA04003124A MX PA04003124 A MXPA04003124 A MX PA04003124A MX PA04003124 A MXPA04003124 A MX PA04003124A
- Authority
- MX
- Mexico
- Prior art keywords
- adenosine
- compound
- hydrogen exchanger
- sodium
- patient
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title abstract 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 title abstract 5
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 title abstract 5
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 title abstract 5
- 229960005305 adenosine Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 230000001270 agonistic effect Effects 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- 230000005961 cardioprotection Effects 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion se dirige a una composicion farmaceutica que comprende un compuesto que tiene actividad agonista de adenosina A1/A2, un compuesto inhibidor de intercambiadores sodio-hidrogeno y un vehiculo farmaceuticamente aceptable; la invencion se dirige tambien a un metodo de proteccion cardiaca en un paciente que lo necesita, que comprende administrar a dicho paciente cantidades farmaceuticamente eficaces de un compuesto que tiene actividad agonista de adenosina A1/A2 y un compuesto inhibidor de intercambiadores sodio-hidrogeno; esta invencion se dirige tambien al uso de cantidades farmaceuticamente eficaces de un compuesto que tiene actividad agonista de adenosina A1/A2 y un compuesto inhibidor de intercambiadores sodio-hidrogeno en la preparacion de un medicamento para proporcionar proteccion cardiaca a un paciente que lo necesita; esta invencion se dirige tambien a un estuche de ensayo para proporcionar proteccion cardiaca en un paciente que lo necesita, comprendiendo dicho estuche de ensayo una pluralidad de recipientes separados, entre los que la menos uno de dichos recipientes contiene un compuesto que tiene actividad agonista de adenosina A1/A2 y al menos otro de dichos recipientes contiene un compuesto inhibidor de intercambiadores sodio-hidrogeno, y dichos recipientes contienen opcionalmente un vehiculo farmaceutico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33631501P | 2001-11-02 | 2001-11-02 | |
| GB0203596A GB0203596D0 (en) | 2002-02-15 | 2002-02-15 | Pharmaceutical composition comprising of adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor |
| PCT/US2002/035096 WO2003039528A1 (en) | 2001-11-02 | 2002-11-01 | Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04003124A true MXPA04003124A (es) | 2004-11-29 |
Family
ID=26246972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04003124A MXPA04003124A (es) | 2001-11-02 | 2002-11-01 | Composicion farmaceutica que comprende un agonista de adenosina a1/a2 y un inhibidor de intercambiadores sodio-hidrogeno. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040248928A1 (es) |
| EP (1) | EP1443916A1 (es) |
| JP (1) | JP2005511590A (es) |
| KR (1) | KR20050042225A (es) |
| CN (1) | CN1585634A (es) |
| BR (1) | BR0213820A (es) |
| CA (1) | CA2465364A1 (es) |
| HR (1) | HRP20040385A2 (es) |
| HU (1) | HUP0401853A2 (es) |
| IL (1) | IL161676A0 (es) |
| MA (1) | MA27073A1 (es) |
| MX (1) | MXPA04003124A (es) |
| NO (1) | NO20042142L (es) |
| PL (1) | PL369074A1 (es) |
| RU (1) | RU2004116686A (es) |
| WO (1) | WO2003039528A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| JP4664797B2 (ja) * | 2005-10-13 | 2011-04-06 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | Ｍｒｉ装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030083004A (ko) * | 1998-02-27 | 2003-10-23 | 화이자 프로덕츠 인크. | 허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화고리)카르보닐] 구아니딘 유도체 |
| CO5180581A1 (es) * | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
-
2002
- 2002-11-01 MX MXPA04003124A patent/MXPA04003124A/es not_active Application Discontinuation
- 2002-11-01 RU RU2004116686/15A patent/RU2004116686A/ru not_active Application Discontinuation
- 2002-11-01 CN CNA028214226A patent/CN1585634A/zh active Pending
- 2002-11-01 EP EP02786638A patent/EP1443916A1/en not_active Withdrawn
- 2002-11-01 BR BR0213820-4A patent/BR0213820A/pt not_active IP Right Cessation
- 2002-11-01 JP JP2003541819A patent/JP2005511590A/ja active Pending
- 2002-11-01 CA CA002465364A patent/CA2465364A1/en not_active Abandoned
- 2002-11-01 WO PCT/US2002/035096 patent/WO2003039528A1/en not_active Application Discontinuation
- 2002-11-01 HU HU0401853A patent/HUP0401853A2/hu unknown
- 2002-11-01 PL PL02369074A patent/PL369074A1/xx not_active Application Discontinuation
- 2002-11-01 IL IL16167602A patent/IL161676A0/xx unknown
- 2002-11-01 KR KR1020047006625A patent/KR20050042225A/ko not_active Application Discontinuation
-
2004
- 2004-04-06 MA MA27610A patent/MA27073A1/fr unknown
- 2004-04-30 HR HR20040385A patent/HRP20040385A2/xx not_active Application Discontinuation
- 2004-04-30 US US10/835,964 patent/US20040248928A1/en not_active Abandoned
- 2004-05-25 NO NO20042142A patent/NO20042142L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20040385A2 (en) | 2005-06-30 |
| US20040248928A1 (en) | 2004-12-09 |
| BR0213820A (pt) | 2004-08-31 |
| RU2004116686A (ru) | 2005-03-27 |
| CN1585634A (zh) | 2005-02-23 |
| KR20050042225A (ko) | 2005-05-06 |
| IL161676A0 (en) | 2004-09-27 |
| JP2005511590A (ja) | 2005-04-28 |
| CA2465364A1 (en) | 2003-05-15 |
| MA27073A1 (fr) | 2004-12-20 |
| PL369074A1 (en) | 2005-04-18 |
| HUP0401853A2 (hu) | 2004-12-28 |
| WO2003039528A1 (en) | 2003-05-15 |
| EP1443916A1 (en) | 2004-08-11 |
| NO20042142L (no) | 2004-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0015605A (pt) | Composição e uso | |
| MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
| MXPA04004779A (es) | Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. | |
| HUP0301194A3 (en) | Pharmaceutical compositions containing combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents and their use for the treatment of diabete mellitus | |
| HUP0203870A2 (hu) | Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény | |
| CA2408142A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
| CA2499330A1 (en) | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | |
| AU3850600A (en) | Dalda analogs and their use | |
| MXPA04005425A (es) | Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer. | |
| UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
| SE9802208D0 (sv) | Novel compounds | |
| AU9551201A (en) | Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates | |
| BR0306928A (pt) | Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace) | |
| MXPA03004209A (es) | Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans. | |
| SG162614A1 (en) | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | |
| GR1004358B (el) | Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης | |
| EP0870502A3 (en) | Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis | |
| MXPA04003124A (es) | Composicion farmaceutica que comprende un agonista de adenosina a1/a2 y un inhibidor de intercambiadores sodio-hidrogeno. | |
| SG162616A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| SE9802209D0 (sv) | Novel compounds | |
| UA83870C2 (ru) | Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1 | |
| GB9930075D0 (en) | Medicaments | |
| GB9930077D0 (en) | Medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |